baclofen / Generic mfg. - LARVOL DELTA

Efficacy and Safety of Baclofen 40 mg/20 mL in an Intrathecal Infusion System. (PubMed, Life (Basel)) - "Switching to baclofen 40 mg/20 mL is safe and clinically equivalent to the conventional 10 mg/5 mL formulation when the daily dose is maintained unchanged. Dose reduction appears unsuitable in patients requiring high daily intrathecal baclofen doses."

Journal • Cerebral Palsy • CNS Disorders • Movement Disorders • Pain

Baclofen Promotes Osteochondrogenic Commitment of Mesenchymal Stem Cells: Implications for Heterotopic Ossification Risk. (PubMed, Int J Mol Sci) - "Under inflammatory conditions, baclofen partially suppressed adipogenesis but did not strongly induce osteochondrogenesis. (4) These findings indicate that baclofen can directly modulate MSC fate, potentially contributing to HO risk, while tizanidine may offer a safer alternative for spasticity management in patients at risk of ectopic bone formation."

Journal • Inflammation • Movement Disorders • IL1B • SPP1

Impact of regulatory changes on the use of baclofen in alcohol use disorders between 2014 and 2021, using the French National Health Data System. (PubMed, Sci Rep) - No abstract available

Journal • Addiction (Opioid and Alcohol)

Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids. (PubMed, J Dermatolog Treat) - "The following local treatment options are described: capsaicin, calcineurin inhibitors, menthol, pramoxine/lidocaine/prilocaine, ambroxol, phenytoin, strontium, amitriptyline, doxepin, duloxetine, baclofen, gabapentin, cannabinoids, loperamide, naltrexone, clonidine, prazosin, acetylsalicylic acid, diclofenac, aprepitant, ketamine, calamine, polidocanol, and botulinum toxin type A. Local therapy offers a valuable and often well-tolerated first step in managing ND...Clinicians are advised to start with low concentrations, discuss off-label use, and monitor for side effects. Until robust guidelines are available, a cautious trial-and-error approach remains the cornerstone of management."

Journal • Review • Dermatology • Neuralgia • Pain • Pruritus

Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review. (PubMed, CNS Drugs) - "Current pharmacological interventions explored in disorders of consciousness target distinct molecular systems, including dopaminergic modulators (amantadine, levodopa, apomorphine, bromocriptine, selegiline, methylphenidate, and modafinil), GABAergic agents (zolpidem and baclofen), and other neuromodulatory compounds acting on glutamatergic, opioid, or serotonergic receptors (ketamine, remifentanil, and psilocin). Safety profiles associated with these treatments are also critically evaluated to guide clinical decision making. By integrating current knowledge on pharmacological modulation of key neural systems, including dopaminergic and GABAergic pathways, this article provides a comprehensive framework for understanding treatment strategies in disorders of consciousness."

Journal • Review

Intrathecal baclofen pump complications in adults: rates, risk factors, and spinal cord injury insights from a longitudinal cohort study. (PubMed, J Neurosurg Spine) - "One in four patients with SCI had complications, half of which occurred within the first year. Younger patients were at higher risk, likely due to increased activity, emphasizing the need for early monitoring and targeted prevention strategies."

Journal • Cardiovascular • CNS Disorders • Diabetes • Infectious Disease • Metabolic Disorders • Multiple Sclerosis • Orthopedics

Pharmacological post-acute treatment of alcohol use disorder: Established strategies and innovative approaches (PubMed, Ther Umsch) - "In Switzerland, four medications (acamprosate, naltrexone, nalmefene, and disulfiram) are approved for post-acute treatment...Baclofen, topiramate, and gabapentin are used "off-label", but sufficient evidence of their effectiveness is still lacking. Innovative approaches such as cannabidiol, psilocybin, and glucagon-like peptide-1 receptor agonists show promising therapeutic potential, which needs to be confirmed in further clinical studies. The use of pharmacological interventions can help improve patient outcomes, reduce the need for inpatient treatment, and lower healthcare costs."

Journal • Review • Addiction (Opioid and Alcohol)

Standard work tools for managing pediatric baclofen pump infections and withdrawal. (PubMed, Childs Nerv Syst) - "SWTs improve safety and timeliness in the management of ITB pump infections and baclofen withdrawal in children. The presented tools provide a reproducible framework for first-line providers and pertinent specialists, particularly for those who may not be familiar with key signs and varied presentations. Broader adoption may reduce variability in treatment while optimizing longitudinal ITB therapy outcomes in pediatric patients."

Journal • Cerebral Palsy • CNS Disorders • Dystonia • Infectious Disease • Movement Disorders • Pediatrics

Integrating addiction care in hepatology: Impact of liver consultation on post-discharge AUD treatment in alcohol-associated hepatitis. (PubMed, J Subst Use Addict Treat) - "Despite hospitalization being a critical opportunity to initiate evidence-based AUD care, most patients with AH did not receive guideline-concordant treatment. Liver consultation services were associated with improved pharmacotherapy delivery and AUD referrals. Embedding addiction treatment protocols within hepatology pathways may improve delivery of AUD care and reduce disparities in this high-risk population."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Hepatology • Inflammation • Psychiatry

AN UNUSUAL CASE OF CEREBELLAR ISCHEMIC STROKE INITIALLY PRESENTING AS ISOLATED HEMIFACIAL SPASM WITHOUT OTHER NEUROLOGICAL SYMPTOMS AND SIGNS (ADPD 2026) - "For now, we report for the first time a rare manifestation of cerebellar ischemic stroke initially presenting isolated hemifacial spasm without other neurological symptoms and signs. As like this case, if there are abrupt-onset isolated hemifacial spasm, it should be considered diagnosis of cerebellar ischemic stroke."

Clinical • Cardiovascular • Ischemic stroke

DIVERSE ALZHEIMER'S DISEASE GENETICS AND MULTI-OMICS DATA FUEL TARGET AND DRUG DISCOVERY: A CASE STUDY FROM THE NIH/NIA AI/ML CONSORTIUM (ADPD 2026) - "Combining genetics and multi-omics data via AI/ML technologies identifies ancestry-specific therapeutic targets and medicines for Alzheimer's disease."

Case study • Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • p-tau181

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol-Associated Cirrhosis. (PubMed, Aliment Pharmacol Ther) - "In this large real-world study, baclofen was associated with a higher risk of hepatic encephalopathy compared with acamprosate in patients with compensated alcohol-associated cirrhosis."

Adverse events • Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatology • Immunology • Liver Failure

Management of Status Dystonicus in the PICU: A Scoping Review of Recent Literature (SCCM 2026) - "There is broad agreement, with some regional variation, on the medical management, with antipyretics, analgesia, sedation (lorazepam), anticholinergics (trihexyphenidyl), muscle relaxants (primarily baclofen and benzodiazepines), alpha-2-adrenergic agonists (clonidine, tizanidine), and the vesicular monoamine transporter (VMAT2) tetrabenazine. Titratable infusions, including midazolam, dexmedetomidine, opioids, and pentobarbital may be needed... Prevention of SD episodes is key. A multidisciplinary, systematic approach to care is essential, with the input of medical, surgical and other subspecialists. Early consideration of interventional approaches in critically ill children with SD is warranted."

Review • CNS Disorders • Dystonia • Infectious Disease • Movement Disorders • Respiratory Diseases • Sleep Disorder

Severe Rhabdomyolysis Presenting in Multisystem Organ Failure in an Adolescent With SC Trait (SCCM 2026) - "His renal function recovered, with secondary hypertension managed with losartan and amlodipine. Mild spasticity in his lower extremities is managed with oral baclofen, and he has full use of all muscle groups. He has not had any recurrence of rhabdomyolysis to date. Pediatric rhabdomyolysis is rare, requiring a high index of suspicion, as the triad of myalgia, muscle weakness, and tea-colored urine is only present in approximately 10% of patients. Consideration of this diagnosis in pediatric patients presenting with AKI, particularly in the presence of associated conditions discussed above, including sickle cell trait, may lead to earlier recognition and prevention of MSOF."

Acute Kidney Injury • Cardiovascular • Epilepsy • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Movement Disorders • Musculoskeletal Pain • Myositis • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases

Are They Truly Brain Dead?! A Case of Baclofen Toxicity Mimicking Brain Death (SCCM 2026) - "Toxicologic mimics of brain death can include baclofen, bupropion, tricyclic antidepressants, and barbiturates.Description: A 55-year-old female was found unresponsive with a suicide note and an empty bottle of Baclofen. In the clinical setting of brain death suspicion, it is important to take sufficient history, perform a thorough physical examination and follow proposed criteria before confirmation. This ensures minimizing unnecessary confirmatory tests as well."

Clinical • CNS Disorders • Depression • Epilepsy • Hypotension

When the Signs Deceive: Lidocaine Toxicity Imitating Brain Death in a Teenager (SCCM 2026) - "Substances such as baclofen and methanol as well as envenomation from specific snake species have been documented to produce exams that are temporarily concerning for BD/DNC...However, lidocaine is not listed as an agent that requires these additional steps. In cases of lidocaine toxicity, it may be beneficial to wait for longer than the recommended amount of time prior to formal evaluation for BD/DNC."

Cardiovascular • CNS Disorders • Cough • Respiratory Diseases

Surgical neuromodulation: prevalence of Staphylococcus aureus, decolonization, and rates of infection. (PubMed, J Neurosurg) - "This study represents the most comprehensive report to date analyzing the prevalence of preoperative MRSA and MSSA colonization in patients undergoing a wide array of surgical neuromodulation procedures. These data support the recommendation that patients receiving neuroimplantable devices, specifically patients undergoing ITB pump procedures, be 1) screened for both MRSA and MSSA, as screening for MRSA alone will not reveal a large fraction of S. aureus colonization; and 2) considered for decolonization protocols prior to surgery. Following these procedures significantly reduced SSIs in patients who underwent ITB pump implantation procedures and might have reduced SSIs for SCS and DBS implantation procedures as well."

Journal • Infectious Disease

Suppression of in vitro epileptiform activity by GABA transaminase inhibition is dependent on GABAB receptors and GABA transporter type 1 (GAT1). (PubMed, J Neurosci) - "The GABAB receptor agonist baclofen caused dose-dependent reduction in frequency of 4AP-induced epileptiform discharges, but did not affect amplitude or duration of discharges. Our data demonstrate that suppression of in vitro epileptiform activity (4-aminopyridine model) after GABA transaminase inhibition with the antiepileptic drug vigabatrin is dependent on GABAB receptors and GIRK channels. GABAB receptor activation is hypothesized to contribute to vigabatrin's clinical efficacy as an antiepileptic drug."

Journal • Preclinical • CNS Disorders • Epilepsy • Mental Retardation • Mood Disorders • Movement Disorders • Psychiatry

Troubleshooting intrathecal pumps in pain management: A clinical review. (PubMed, Interv Pain Med) - "While there is overlap with existing literature on intrathecal baclofen therapy, the clinical presentation and work-up varies when utilizing opioids and local anesthetics. Therefore, we propose a stepwise framework for troubleshooting intrathecal pump therapy in the setting of non-baclofen medications."

Journal • Review • Addiction (Opioid and Alcohol) • Anesthesia • Oncology • Pain

NL 68837.091.21: Pulmonary function and sleep related disorders during cervical admission of intrathecal baclofen in spinal cord injury;na safety study (clinicaltrialsregister.eu) - P4 | N=11 | Active, not recruiting | Sponsor: Roessingh Centrum Voor Revalidatie | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Orthopedics

Bridging genomics and pharmacoepidemiology to expand treatment options for alcohol use disorder. (PubMed, Alcohol Clin Exp Res (Hoboken)) - "This approach, which aligns genomic findings with real-world clinical data, provides an efficient method for identifying promising drug repurposing candidates and prioritizing those that merit evaluation in randomized trials to ultimately advance pharmacotherapies for AUD."

Journal • Addiction (Opioid and Alcohol)

Preclinical Evidence Supporting Pilavapadin as a Novel Oral Therapy for Spasticity (AAN 2026) - "Objective: To evaluate the effects of the adapter protein-2 associated kinase 1 (AAK1) inhibitor pilavapadin on spasticity endpoints in preclinical models of central nervous system injury.Background: Current oral therapies for spasticity, such as baclofen and tizanidine, provide only partial benefit and are often limited by sedation... In mice, pilavapadin significantly improved tcMEP latency (5.55 ± 0.22ms at 10 mg/kg; 5.32 ± 0.22ms at 3 mg/kg vs. 10.05 ± 2.59ms for vehicle; both p<0.05) and peak-to-peak amplitude (11,613.75 ± 1154.41 µV at 10 mg/kg; 11,321.67 ± 1321.68 µV at 3 mg/kg vs. 7681.17 ± 1505.12 µV for vehicle; both p<0.001) on day 10, with effects comparable to fingolimod and tizanidine... Pilavapadin demonstrated significant, sustained effects measures of spasticity in two validated preclinical models. These findings support further development of pilavapadin as a potential oral therapy for spasticity with a..."

Preclinical • CNS Disorders • Depression • Movement Disorders • Multiple Sclerosis

Case Report: Interleukin-23 blockade achieves sustained remission in Niemann-Pick type C-associated Crohn's disease refractory to anti-tumor necrosis factor therapy. (PubMed, Front Immunol) - "Adalimumab was not successful in maintaining remission despite corticosteroid therapy. Ustekinumab induced steroid-free remission...Switching to risankizumab achieved stable remission, which was maintained for 3 years. During interleukin (IL)-23 blockade therapy, the patient developed an infection associated with an intrathecal baclofen pump...Furthermore, it supports the hypothesis that IL-23-driven inflammation plays a role in the development of this condition. These findings should be considered hypothesis-generating and validated in additional cases."

Journal • Crohn's disease • Frontotemporal Lobar Degeneration • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Infectious Disease • Inflammatory Bowel Disease • Lysosomal Storage Diseases • Metabolic Disorders • Oncology • IL12A • IL23A

Baclofen for Children With Rumination Syndrome (clinicaltrials.gov) - P3 | N=50 | Completed | Sponsor: Nationwide Children's Hospital | Recruiting ➔ Completed

Trial completion

Renal Roulette: Perils of Baclofen Overdose and Withdrawal (NKF-SCM 2026) - "CONCLUSION Baclofen toxicity and withdrawal can be life-threatening, even when baseline kidney function is normal. Close renal monitoring, supportive care, and careful baclofen reintroduction are key."

CNS Disorders • Depression • Hypotension • Renal Disease